Reports on Liposomes Findings from Xi'an Jiaotong University Provide New Insights (Engineering Pd-l1 Targeted Liposomal Canagliflozin Achieves Multimodal Synergistic Cancer Therapy).

A study conducted at Xi'an Jiaotong University in China explores the potential of using a nanoliposome coated with a PD-L1-targeting peptide to deliver canagliflozin, a drug for type II diabetes, for cancer therapy. The research delves into the antitumor mechanisms of canagliflozin, highlighting its ability to suppress signaling pathways, induce PD-L1 degradation, and sensitize tumors to radiation. The study concludes that this targeted delivery system could achieve multimodal synergistic cancer therapy, offering new possibilities for clinical treatment. [Extracted from the article]